The Asia Pacific Healthcare Bioconvergence Market would witness market growth of 7.4% CAGR during the forecast period (2022-2028).
The examination of nature and its mechanics, models, and their application to the process of the invention is exactly what the Bioconvergence technique entails. This strategy has been gaining ground in the sciences, particularly the life sciences and medical innovation, and for a good cause.
It enables innovators to not only produce better goods and have a genuine impact but also to gain access to more and better capital, which facilitates the creation of these superior products' businesses and their commercialization. The aim to offer consumers better healthcare goods and services led to this amazing development in biosciences.
The healthcare system has undergone significant modifications and revisions recently in an effort to offer the world's population more affordable and efficient medical care. Researchers from all around the world have been examining how to use and mimic nature to treat the majority of the diseases that plague the global populace.
China's population is aging at one of the fastest rates in the world. Due to rising life expectancy and falling birth rates, 28% of China's population is expected to be over 60 by 2040. For public health and socioeconomic development, this profound demographic shift creates a number of new challenges and opportunities. Of particular importance is the creation of an integrated system that meets the social and health needs of older people while ensuring that everyone has access to healthcare, regardless of location.
The China market dominated the Asia Pacific Engineered Living Materials Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $808.3 million by 2028. The Japan market is estimated to grow a CAGR of 8.1% during (2022 - 2028). Additionally, The India market would display a CAGR of 9.4% during (2022 - 2028).
Based on Application, the market is segmented into Drug Discovery, Precision Medicine, Regenerative Medicine, Diagnostic & Biological Sensors, Bioelectronics, Nanorobotics for Drug Delivery, Engineered Living Materials, and Optogenetics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Healthcare Bioconvergence Market is Projected to reach USD 169.9 Billion by 2028, at a CAGR of 7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BiomX, Inc., Singota Solutions, Anima Biotech Inc., Ginkgo Bioworks Holdings, Inc., SetPoint Medical Corporation, Galvani Bioelectronics, Ltd. (GlaxoSmithKline plc and Verily Life Sciences), and BICO Group AB (publ).
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
